Australia Stock Exchange release from PHARMAUST : MND & COVID-19 Phase 1 Clinical Trials On-Track
16/11/2021 21:23
Australia Stock Exchange release from PHARMAUST PAA.AX : MND & COVID-19 Phase 1 Clinical Trials On-Track
Recent news on Neurizon Therapeutics
See all newsAustralia's Neurizon Therapeutics jumps on deal with US firm
Brief: Neurizon Therapeutics Executes Long-Term Supply Agreement With Elanco
Brief: Neurizon Therapeutics Receives Ethics Approval For Phase 1 Nuz-001 Oral Liquid Formulation Study
Brief: Neurizon Therapeutics Announces Placement Of Entitlement Offer Shortfall To Raise ~A$2.7 Million
Brief: Neurizon Therapeutics Says Michael Thurn Resigns As Managing Director And CEO